Sanofi's Q2 2026 earnings call, held on July 30, 2026, focused on a sweeping pipeline review that included abandoning amlitelimab despite positive Phase III data, while new CEO Belen Garijo signaled stricter R&D portfolio discipline.

Q2 net sales grew 17.8% to EUR 11.6 billion, driven primarily by volume; full-year 2026 guidance was upgraded to approximately 10% sales growth at constant exchange rates, with business earnings per share growing slightly faster than sales.

Key Strategic Signals

  • Amlitelimab dropped despite positive Phase III extension data: Sanofi decided not to seek approval for anti-OX40L monoclonal antibody amlitelimab in atopic dermatitis after reviewing the totality of its Phase III efficacy and safety data, despite ESTUARY showing maintenance of response for up to 72 weeks. The decision removes what had been regarded as a potential competitor to dupilumab (Dupixent) from Sanofi's own pipeline.
  • Broad immunology discontinuations signal portfolio thinning: Itepekimab, an anti-IL-33 antibody, was discontinued across chronic obstructive pulmonary disease and chronic rhinosinusitis; balinatunfib was stopped after Phase II studies in Crohn's disease and ulcerative colitis failed to meet internal efficacy expectations; and riliprubart, an anti-C1s antibody, was halted in refractory chronic inflammatory demyelinating polyneuropathy (CIDP) following an independent data monitoring committee recommendation that the primary endpoint was unlikely to be met. CEO Belen Garijo said Sanofi would apply greater scientific rigor and fact-based decision-making to Phase II-to-Phase III transitions, arguing that weaknesses in those decisions had contributed to recent pipeline setbacks. Notably, further pipeline cuts were not ruled out by Garijo: "The pipeline review is ongoing. So I'm not excluding that we discontinue some additional assets... We don't have a target number to discontinue".
  • Efdoralprin alfa and venglustat emerge as near-term regulatory catalysts: Phase II data for efdoralprin alfa, an alpha-1 antitrypsin deficiency (AATD) therapy presented at the American Thoracic Society meeting, showed mean functional AAT trough levels more than 3x higher than weekly plasma-derived AAT at week 32, with a comparable safety profile; management said these data will support a first FDA submission in H2 2026. Separately, venglustat, a glucosylceramide synthase inhibitor, received US priority review for Type 3 Gaucher disease with a target action date of November 25, 2026 following positive Phase III results in LEAP2MONO. The milestone came after Sanofi discontinued development in Fabry disease when the PERIDOT Phase III trial failed to meet its primary endpoint, leaving Gaucher disease as the program's lead indication.
  • Duvakitug expands into new indications: Sanofi and Teva said they plan to initiate Phase II studies of the TL1A antibody duvakitug in hidradenitis suppurativa and fibrostenotic Crohn’s disease, adding to ongoing development in Crohn’s disease and ulcerative colitis.

Analyst Pressure Points

  • Frexalimab Phase III endpoint risk: JPMorgan's Richard Vosser raised concerns about frexalimab, an anti-CD40L antibody, noting questions about the primary endpoint's ability to differentiate from teriflunomide (Aubagio) in relapsing multiple sclerosis (RMS). CSO Mike Quigley said the company has been working with global regulators to refine the statistical analysis plan, confirmed the annual relapse rate primary endpoint is unchanged, and said key secondary endpoints — including six-month confirmed disability progression — will also be reported. Phase III RMS data are expected in 2027, secondary progressive multiple sclerosis data in 2028.
  • Riliprubart VITALIZE trial viability questioned: Following the halt of the MOBILIZE study in refractory CIDP, Vosser pressed management on whether the VITALIZE trial — studying riliprubart versus intravenous immunoglobulin (IVIg) in IVIg-treated patients still progressing — faced analogous risks. Quigley said the two patient populations are distinct, noted the independent data monitoring committee reviewed VITALIZE alongside MOBILIZE and recommended it continue, and confirmed the readout is expected in the latter half of 2027.

Forward-Looking Catalysts

  • Sarclisa transplant-eligible myeloma readout expected in H2 2026: Management said the final Phase III data for isatuximab (Sarclisa) in transplant-eligible multiple myeloma are expected before year-end, with a US label expansion anticipated on the basis of that data.
  • Frexalimab RMS Phase III readout in 2027: The Phase III relapsing multiple sclerosis data represent the most significant binary pipeline event on the near-term horizon, given the size of the multiple sclerosis market and the absence of a clear successor to Aubagio, which faces generic competition, in Sanofi's neurology franchise.
  • Nexviazyme label expansion discussions with FDA: Phase III data showed 94% of infants with infantile-onset Pompe disease alive and free from invasive ventilation at week 52 across all key secondary endpoints; management said these results will support FDA discussions on a US label expansion for avalglucosidase alfa, noting approvals have already been secured in other markets.

Access the AllSci platform to explore the science behind the news.

Spot something wrong? Report an issue with this article